中山大学中山眼科中心
Zhongshan Ophthalmic Center
在本站收录的 53 种疾病中,这家医院列在其中 5 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。
这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。
这家医院的官网还没有核对。
中山大学中山眼科中心的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 视网膜母细胞瘤Retinoblastoma25 篇牵头论文牵头 1 项开放试验
- 神经母细胞瘤Neuroblastoma0 篇牵头论文
- 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder4 篇牵头论文
- 白塞病Behçet disease7 篇牵头论文
- Leber 遗传性视神经病变Leber hereditary optic neuropathy3 篇牵头论文
未列出的收录疾病:鼻咽癌、食管鳞状细胞癌、肝细胞癌、胃癌、肝母细胞瘤、脊索瘤、骨肉瘤、胃肠道间质瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、特发性肺纤维化、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
视网膜母细胞瘤
Retinoblastoma2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 25 篇,占 8.3%。
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 8 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma
- 分期
- III期
- 开始
- 2020-11
- 登记号
- NCT05080010
年龄未注明(登记的条件)
牵头:中山大学中山眼科中心广州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文25
- Loss of ELF2 drives topotecan resistance in retinoblastoma revealed by genome-wide CRISPR-Cas9 screening.
- MTHFD2 drives retinoblastoma progression via Notch signaling activation: Implications for targeted pediatric ocular cancer therapy.
- Targeting MCM6 Enhances Melphalan Chemosensitivity in Retinoblastoma by Modulating DNA Damage Response.
- SOX4 as a Key Oncogene Driving Tumor Invasion in Retinoblastoma.
- The role of lactate metabolism in retinoblastoma tumorigenesis and ferroptosis resistance.
- Comprehensive identification of pathogenic variants in retinoblastoma by long- and short-read sequencing.
- Single-cell transcriptomics enable the characterization of local extension in retinoblastoma.
- PRMT1 mediates the proliferation of Y79 retinoblastoma cells by regulating the p53/p21/CDC2/cyclin B pathway.
- Heterogeneous Expression Patterns of the Minichromosome Maintenance Complex Members in Retinoblastoma Unveil Its Clinical Significance.
- Three vs 6 Cycles of Chemotherapy for High-Risk Retinoblastoma: A Randomized Clinical Trial.
- Polyester 5-0 suture for porous implant placement after retinoblastoma enucleation: analysis of 120 sockets.
- Expression of YAP suppresses cell proliferation and elevates the sensitivity of chemotherapy in retinoblastoma cells through lipid-peroxidation induced ferroptosis.
- EZH2 Expression in Retinoblastoma: A Potential Therapeutic Target.
- Generation and characterization of two induced pluripotent stem cell lines from conjunctiva of a retinoblastoma patient.
- Single-cell characterization of malignant phenotypes and microenvironment alteration in retinoblastoma.
- Kruppel-like factor 2 acts as a tumor suppressor in human retinoblastoma.
- Bioinformatics Analysis and Experimental Identification of Immune-Related Genes and Immune Cells in the Progression of Retinoblastoma.
- Targeting of histone methyltransferase DOT1L plays a dual role in chemosensitization of retinoblastoma cells and enhances the efficacy of chemotherapy.
- Retinoblastoma cell-derived exosomes promote angiogenesis of human vesicle endothelial cells through microRNA-92a-3p.
- Ubiquitination-Related miRNA-mRNA Interaction Is a Potential Mechanism in the Progression of Retinoblastoma.
- Chromatin regulators in retinoblastoma: Biological roles and therapeutic applications.
- Efficient assembly of nanopore reads via highly accurate and intact error correction.
- Exosomes derived from retinoblastoma cells enhance tumour deterioration by infiltrating the microenvironment.
- Therapeutic Targeting PLK1 by ON-01910.Na Is Effective in Local Treatment of Retinoblastoma.
- RNA Sequencing and Bioinformatic Analysis on Retinoblastoma Revealing that Cell Cycle Deregulation Is a Key Process in Retinoblastoma Tumorigenesis.
早期论文(2016–2020 年)13
- Effectiveness of intravitreal chemotherapy-assisted endoresection in monocular patients with group D retinoblastoma.
- UHRF1 downmodulation enhances antitumor effects of histone deacetylase inhibitors in retinoblastoma by augmenting oxidative stress-mediated apoptosis.
- Artesunate induces mitochondria-mediated apoptosis of human retinoblastoma cells by upregulating Kruppel-like factor 6.
- Associations among Socioeconomic Factors, Lag Time, and High-Risk Histopathologic Features in Eyes Primarily Enucleated for Retinoblastoma.
- Identification of stemness in primary retinoblastoma cells by analysis of stem-cell phenotypes and tumorigenicity with culture and xenograft models.
- Tetramethylpyrazine downregulates transcription of the CXC receptor 4 (CXCR4) via nuclear respiratory factor‑1 (Nrf‑1) in WERI‑Rb1 retinoblastoma cells.
- UHRF1 depletion sensitizes retinoblastoma cells to chemotherapeutic drugs via downregulation of XRCC4.
- Regulated differentiation of WERI-Rb-1 cells into retinal neuron-like cells.
- An optimized gene transfection system in WERI-Rb1 cells.
- Tetramethylpyrazine-mediated regulation of CXCR4 in retinoblastoma is sensitive to cell density.
- Functional dissection of the role of UHRF1 in the regulation of retinoblastoma methylome.
- The Potential Benefit of Three vs. Six Cycles of Carboplatin, Etoposide, and Vincristine in Postenucleation High-Risk Patients with IRSS Stage I Retinoblastoma.
- Thrombospondin-1 might be a therapeutic target to suppress RB cells by regulating the DNA double-strand breaks repair.
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
- Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma
- Efficacy Study of Lucentis in the Treatment of Retinoblastoma
- Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation
- Attention to Retinoblastoma Diagnosed in the Trauma Setting
- Carboplatin Periocular Injection for Retinoblastoma
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年没有牵头神经母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 23 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。
其他疾病
视神经脊髓炎谱系疾病
Neuromyelitis optica spectrum disorder2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 9 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的视神经脊髓炎谱系疾病开放试验。
这些数字背后的记录
牵头的论文4
- Inhibition of C3/C3aR Pathway Alleviates Visual and Optic Nerve Impairments in a Rat Model of Neuromyelitis Optica Spectrum Disorder.
- Different visual evoked potentials in neuromyelitis optica spectrum disorder-related optic neuritis and idiopathic demyelinating optic neuritis: a prospective longitudinal analysis.
- Comparing evolvement of visual field defect in neuromyelitis optica spectrum disorder-optic neuritis and idiopathic optic neuritis: a prospective study.
- Comparison of macular structural and vascular changes in neuromyelitis optica spectrum disorder and primary open angle glaucoma: a cross-sectional study.
其他疾病
白塞病
Behçet disease2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 7 篇,占 2.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 7 家医院列在白塞病下全国有 149 家医院列在白塞病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。
这些数字背后的记录
牵头的论文7
- NETs-CD44-IL-17A Feedback Loop Drives Th17-Mediated Inflammation in Behçet's Uveitis.
- Single-cell transcriptomic profiling reveals aberrant CD4⁺ naive T cell differentiation driving immune activation in Behçet's uveitis.
- Successful Remission with Upadacitinib in Two Patients with Anti-TNF-Refractory Macular Edema Associated with Behçet's Uveitis.
- Intravitreal dexamethasone implants facilitate the management of refractory Behçet's uveitis with vasculitis.
- Single-cell chromatin accessibility and transcriptomic characterization of Behcet's disease.
- Macrophage-like Cells Characterized by En Face Optical Coherence Tomography was Associated with Fluorescein Vascular Leakage in Behçet's Uveitis.
- Comparative study of adalimumab versus conventional therapy in sight-threatening refractory Behçet's uveitis with vasculitis.
早期论文(2016–2020 年)1
其他疾病
Leber 遗传性视神经病变
Leber hereditary optic neuropathy2021–2025 年中国大陆作者发表的 52 篇Leber 遗传性视神经病变 PubMed 英文论文中,这家医院牵头了 3 篇,占 5.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 1 家医院列在Leber 遗传性视神经病变下全国有 32 家医院列在Leber 遗传性视神经病变下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Leber 遗传性视神经病变开放试验。
这些数字背后的记录
牵头的论文3
- Clinical and genetic landscape of optic atrophy in 826 families: insights from 50 nuclear genes.
- Variant and clinical landscape of Leber hereditary optic neuropathy based on 1516 families with mtDNA variants in a tertiary centre.
- Non-Pharmaceutical Interventions against COVID-19 Causing a Lower Trend in Age of LHON Onset.
早期论文(2016–2020 年)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他相关研究
联系这家医院
出示给工作人员或司机的院名卡
中山大学中山眼科中心
Zhongshan Ophthalmic Center
广州
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药